Literature DB >> 7538616

The insulin-like growth factor system in regulation of normal and malignant hematopoiesis.

I Shimon1, O Shpilberg.   

Abstract

The published data available on the insulin-like growth factor (IGF) family of peptides, its receptors and binding proteins in connection with normal and neoplastic hematopoietic processes are reviewed. It is found that nearly all the different hematopoietic cells, either normal or neoplastic, express IGF receptors. The IGFs are involved in normal erythropoiesis, granulopoiesis and lymphopoiesis. IGFs, especially IGF-1, are mitogenic for cell lines of myeloid and lymphoid leukemias and Burkitt's lymphoma. Differentiation of certain immature malignant cell lines is associated with a decrease in the number and affinity of IGF receptors. It might be concluded that the IGFs have an important role in the physiologic and neoplastic processes of the hematopoietic system, and the expanding knowledge of this issue will contribute to the understanding of proliferation and differentiation processes in specific hematologic disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538616     DOI: 10.1016/0145-2126(94)00133-u

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  23 in total

1.  INSULIN-LIKE GROWTH FACTOR-1 AND ANEMIA IN OLDER SUBJECTS: THE INCHIANTI STUDY.

Authors:  Francesca De Vita; Marcello Maggio; Fulvio Lauretani; Lara Crucitti; Stefania Bandinelli; Federica Mammarella; Francesco Landi; Luigi Ferrucci; Gian Paolo Ceda
Journal:  Endocr Pract       Date:  2015-07-27       Impact factor: 3.443

2.  Refinement of cytokine use in the in vitro expansion of erythroid cells.

Authors:  Ken-Ichi Miharada; Takashi Hiroyama; Kazuhiro Sudo; Toshiro Nagasawa; Yukio Nakamura
Journal:  Hum Cell       Date:  2006-02       Impact factor: 4.174

3.  Preparation of a recombinant chimaera of insulin-like growth factor II and interleukin 3 with high proliferative potency for haemopoietic cells.

Authors:  M R Difalco; L F Congote
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

Review 4.  Big babies and infant leukemia: a role for insulin-like growth factor-1?

Authors:  J A Ross; J P Perentesis; L L Robison; S M Davies
Journal:  Cancer Causes Control       Date:  1996-09       Impact factor: 2.506

5.  Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Jenny N Poynter; Michaela Richardson; Cindy K Blair; Michelle A Roesler; Betsy A Hirsch; Phuong Nguyen; Adina Cioc; Erica Warlick; James R Cerhan; Julie A Ross
Journal:  Cancer Epidemiol       Date:  2015-12-22       Impact factor: 2.984

6.  Trends in childhood leukemia incidence over two decades from 1992 to 2013.

Authors:  Jessica L Barrington-Trimis; Myles Cockburn; Catherine Metayer; W James Gauderman; Joseph Wiemels; Roberta McKean-Cowdin
Journal:  Int J Cancer       Date:  2016-11-30       Impact factor: 7.396

7.  High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia.

Authors:  Andrea Kühnl; Martin Kaiser; Martin Neumann; Lars Fransecky; Sandra Heesch; Michael Radmacher; Guido Marcucci; Clara D Bloomfield; Wolf-Karsten Hofmann; Eckhard Thiel; Claudia D Baldus
Journal:  Leuk Res       Date:  2011-09-06       Impact factor: 3.156

8.  Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation.

Authors:  S Weischendorff; K Kielsen; H Sengeløv; K Jordan; C H Nielsen; A E Pedersen; L P Ryder; A Juul; K G Müller
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

Review 9.  Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors.

Authors:  G S Chatta; D C Dale
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

10.  Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort.

Authors:  Xiaomei Ma; Unhee Lim; Yikyung Park; Susan T Mayne; Rong Wang; Patricia Hartge; Albert R Hollenbeck; Arthur Schatzkin
Journal:  Am J Epidemiol       Date:  2009-04-24       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.